Periodic Reporting for period 1 - WOUNDCOM (Interactive biomembranes for wound management – exploiting the unique wound healing and antimicrobial properties of human collagen VI)
Reporting period: 2018-08-01 to 2019-01-31
The available wound care options can manipulate one or multiple aspects of the wound environment, but cannot form an antibacterial barrier and facilitate healing to a satisfactory level at the same time. Colzyx aims to address this challenge and unmet need by developing its bioactive wound dressing that will make use of the newly discovered wound healing and antimicrobial properties of human collagen VI and parts thereof. WOUNDCOM is to be used in all post-surgery treatment mediating rapid wound healing and antimicrobial effect and, above all, in the treatment of chronic wounds, such as diabetic foot and venous leg ulcers.
The overall objectives of this project were to develop and optimise business plan that will guide exploitation and commercialisation of Colzyx’s novel dressing that 1) promotes rapid wound closure, 2) promotes normal wound healing, 3) reduces scar complications and tissue contractions, and 4) reduced the risk of bacterial infection. Moreover, our goal was to define success factors, revenue goals and assess WOUNDCOM’s health economic potential.
The overall objectives of this project were to develop and optimise business plan that will guide exploitation and commercialisation of Colzyx’s novel dressing that 1) promotes rapid wound closure, 2) promotes normal wound healing, 3) reduces scar complications and tissue contractions, and 4) reduced the risk of bacterial infection. Moreover, our goal was to define success factors, revenue goals and assess WOUNDCOM’s health economic potential.
Colzyx used Strategic Business Planning Methodology to perform the feasibility study, which will then guide the overall business development strategy. It provided a valuable understanding of the current trends and opportunities on the wound management market, targeted users, competitors and potential partnerships. A work plan for the clinical study to evaluate WOUNDCOM’s performance, safety and tolerability in patients with chronic wounds was also developed as part of this project.
The feasibility study has confirmed that there is a clear business opportunity to exploit the global wound care market and to deliver the first-in-class bioactive product for effective wound care management.
The feasibility study has confirmed that there is a clear business opportunity to exploit the global wound care market and to deliver the first-in-class bioactive product for effective wound care management.
This feasibility study has confirmed the innovative character of Colzyx’s approach. The novelty of our wound dressing goes beyond the state of the art in wound care. Basing on a ground-breaking discovery of wound healing and antimicrobial properties of human collagen VI and parts thereof, Colzyx has developed the product that has the potential to revolutionise the wound management market and create a new category of interactive biomembranes. Chronic wounds are a global problem as they decrease patients’ quality of life and generate high medical costs. Novel wound care products addressing both: rapid wound closure and combat of infections are urgently needed and Colzyx aims to address unmet challenge with its product.